Background. -Karolinska Rennes (KaRen) is a prospective observational study to characterize heart failure patients with preserved ejection fraction (HFpEF) and to identify prognostic factors for long-term mortality and morbidity. Aims. -To report characteristics and echocardiography at entry and after 4-8 weeks of followup.
Introduction
In recent years, heart failure with preserved ejection fraction (HFpEF) has been increasingly recognized as a pathophysiological entity [1] . The proportion of patients with heart failure with HFpEF is about 50% of the general heart failure population [2] [3] [4] . In epidemiological surveys, the prognosis of HFpEF is nearly as poor as for heart failure with reduced ejection fraction (HFrEF) [5] [6] [7] [8] . Despite extensive efforts to characterize HFpEF [9] and several randomized therapeutic trials, little is known about the clinical course and treatment options for this condition. Guidelines are therefore still restricted to modifying the risk factors predominant in HFpEF, such as to obtain strict control of blood pressure or to treat symptoms of congestion with diuretics [10] .
Current guidelines highlight the importance of additional objective criteria to signs and symptoms and preserved or normal ejection fraction for the diagnosis of HFpEF [9] [10] [11] . These criteria include normal left ventricular volume, increased left atrial volume, left ventricular hypertrophy and/or diastolic dysfunction and natriuretic peptides [12] , whereas diagnostic criteria for dyssynchrony are not included. Little is known about the role of electrical and mechanical dyssynchrony in HFpEF [13, 14] . A typical left bundle branch block (LBBB) was found in 14.4% of patients included in CHARM-Preserved [15] and 8.1% in I-PRESERVE [16] . In ischemic HFpEF, it has been demonstrated that both left ventricular diastolic and atrial mechanical dyssynchrony may impair diastolic function [17] . It has therefore been suggested that dyssynchrony may contribute to the pathophysiology of HFpEF, warranting the need for a prospective study to analyse the importance of these factors [17, 18] .
To further characterize HFpEF patients and to look for new therapeutic options in these patients, we conducted a prospective registry study of HFpEF patients admitted for an acute heart failure exacerbation in Sweden and France -the Karolinska Rennes (KaRen) study [19] . The aim of this report is to describe and compare the clinical and basic echocardiographic characteristics of the study populations at acute presentation and at 4-8-week follow-up.
Methods
The rationale and design of the KaRen study have previously been published [19] . Briefly, KaRen is a prospective, multicentre, international, observational study with the primary objective to determine whether electrical or mechanical dyssynchrony independently affects the prognosis. The present work sought to characterize the HFpEF patients included in KaRen according to their main clinical, electrocardiographic (ECG) and echocardiographic characteristics. Patients were included in KaRen between 1 May 2007 and 1 December 2011 in 10 French and three Swedish university hospitals. Details on inclusion and exclusion criteria have been published [19] . Patients were recruited consecutively as far as was possible. We aimed to identify at least 400 patients seeking medical attention in the emergency department with clinical signs and symptoms of heart failure according to the Framingham criteria [13] . A left ventricular ejection fraction (LVEF) ≥ 45% by echocardiography and natriuretic peptides (B-type natriuretic peptide [BNP] > 100 ng/L or N-terminal pro-BNP [NT-proBNP] > 300 ng/L) were also required. All three inclusion criteria (clinical heart failure, LVEF and peptides) had to be verified within 72 hours of presentation.
Anemia was defined as hemoglobin < 120 g/L in women and < 130 g/L in men, and renal dysfunction as serum creatinine > 120 mol/L or an estimated glomerular filtration rate (eGFR) < 60 mL/min. Coronary artery disease was defined as a history of acute myocardial infarction, coronary artery bypass or angioplasty or > 50% coronary artery stenosis on a coronary angiogram. Clinical heart failure signs were classified as signs of left heart failure, right heart failure or both [19] .
Patients who presented acutely with heart failure were screened, and patients were included based on inclusion criteria in the acute state including conventional assessment of ejection fraction, but with no detailed analysis of other parameters. Patients returned to a stable state (with or without hospitalization) according to the conventional treatment decided by individual investigators. After 4-8 weeks, included patients returned to the hospital for exhaustive clinical, ECG and biological reassessment and a detailed echocardiographic study. These half-day visits were stringently analysed in dedicated core centres. Follow-up was continued for ≥ 18 months.
In this report, we describe the clinical and basic echocardiographic characteristics of patients in KaRen at baseline and at 4-8-week follow-up. The description is based on cut-off values published in 2007 in a consensus paper about HFpEF [9] and according to the American Society of Echocardiography (ASE)/European Association of Echocardiography (EAE) recommendations for chamber quantification in echocardiography [20] .
Statistical analysis
Continuous variables are presented as means ± standard deviations (SDs) and/or medians (interquartile ranges [IQR]). Categorical variables are presented as counts and percentages.
To compare the means of measurements performed at two time points (baseline and 4-8 weeks), we used Student's t test to produce a statistic for the null hypothesis that the mean difference equals zero. All P-values are two-sided and statistical significance was set at 0.05. All analyses were performed using SAS ® 9.3 Statistical Procedures (SAS Institute Inc., Cary, NC, USA).
Results
The flow chart of the KaRen study is shown on Fig. 1 . Patients (n = 584) were considered for inclusion in KaRen between 1 May 2007 and 1 December 2011. Of these, 29 did not meet inclusion criteria and 16 withdrew consent. Thus, 539 patients were enrolled in the study and assessed at baseline. Of these, 470 patients were admitted to hospital for heart failure treatment and 69 were sent home after treatment revision. Thirteen patients (2.4%) died and 21 (3.9%) were re-hospitalised for heart failure between enrolment and the 4-8-week visit. A total of 101 patients did not return for the 4-8-week follow-up visit, leaving 438 who were re-assessed at the 4-8-week visit. Apart from older mean age (80 ± 9 vs. 76 ± 9 years; P = 0.006), there were no statistically significant differences in baseline characteristics between patients who returned for the follow-up visit and those who did not. 
Characteristics at acute admission and 4-8 weeks
The mean age of the 539 patients was 77 ± 9 years, and 56% were women (Table 1) . A history of heart failure was found in 40%. The history of heart failure symptoms revealed that 80% of patients had been New York Heart Association (NYHA) class I/II before the exacerbation of acute heart failure, but at admission, most patients (90%) were NYHA III/IV. Mean LVEF at admission was 56 ± 7%, and 303 (56%) had LVEF > 55%. At admission, 456 patients (85%) had ≥ two major and 83 (15%) had one major and ≥ two minor Framingham criteria for heart failure. Median NT-proBNP was 2448 ng/L and median BNP 439 was 429 ng/L ( Table 1) 
ECG and echocardiographic measurements at 4-8 weeks ECG
At 4-8 weeks, 244 were classified as ''no atrial arrhythmia'' out of 378 (64.55%). Conduction disturbances were rare among these patients, with only 28 out of 244 (11.48%), 13.5% having a long PR interval (> 200 ms) and 52 out of 348 not V-paced patients (14.94%) having a QRS width > 120 ms (Table 1) . Right bundle branch block (RBBB) was present in 31 out of 348 (8.91%) and LBBB in 24 out of 348 (6.90%). Table 2 contains echocardiographic characteristics at 4-8 weeks. LVEF was preserved, but was significantly lower at baseline than at the 4-8-week visit (56 ± 7% vs. 62 ± 7%; P < 0.001). Left ventricular fractional shortening was > 30% for most patients (207/356; 61%). Left ventricular s' was > 7 cm/s for 105/356 (30%). Left ventricular global longitudinal strain (GLS) was < −16% for 139/356 (67%).
Left ventricular ejection fraction

Left ventricular volumes
A total of 218/356 patients (63%) had a left ventricular end-diastolic volume ≤ 97 mL/m 2 , showing no significant left ventricular enlargement [9] . Fig. 3 highlights the importance of diastolic dysfunction and the association of enlarged left atrium and persistent E/e > 12 at 4-8 weeks. E/e > 15 was only found at the 4-8-week visit for 94/356 patients (28%), but diastolic dysfunction was severe as e' was < 11 cm/s for 310/356 patients (88%). Also, left atrial indexed volume was > 32 mL/m 2 (a predictor of cardiovascular events [9] ) for 220/356 patients (85%).
Diastolic function
Left ventricular hypertrophy
Signs of left ventricular hypertrophy were found on ECG in a minority of patients (25/356; 5%), but echocardiography showed left ventricular hypertrophy in 39% of patients.
Medication
The prescription rates of angiotensin-converting-enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs) and beta-blockers were 60% and 64%, respectively, at admission and increased by around 10% at discharge ( Table 3 ). The prescription rate of K + -sparing diuretics was low, but doubled from 10% to 22% between admission and 4-8-week follow-up. More than half of the patients (60%) were on loop diuretics at admission, and this increased to 83% at 4-8 weeks, with a median (range) dose of furosemide at 4-8 of 40 (20-1000) mg/day. Diuretics were discontinued in 29 patients after enrolment, whereas 43 patients never received diuretics. Conversely, the prescription rate of calcium antagonists (34% at admission) decreased somewhat over time. Anti-arrhythmic drugs were used in 15% and did not increase over time.
Discussion
KaRen prospectively included a population of HFpEF patients as strictly defined by validated Framingham criteria, preserved ejection fraction and elevated natriuretic peptides. The short-term mortality was low. The populations at entry and 4-8-week follow-up were generally similar, except for lower LVEF at study entry. After 4-8 weeks of dedicated treatment, an important proportion of patients still showed symptoms and signs of heart failure. Aetiological factors and co-morbid conditions were as previously described for HFpEF patients [2] [3] [4] [5] , with a high proportion of female gender, hypertension and atrial tachyarrhythmias. Diagnostic criteria for HFpEF left ventricular diastolic dysfunction, according to guideline criteria, were frequently observed, and left ventricular systolic dysfunctions were frequently found despite LVEF > 45%. Also, dyssynchrony as classically defined by bundle branch block or atrioventricular conduction abnormalities does not seem to be a strong determinant in HFpEF. 
Baseline characteristics in KaRen and clinical presentation
The KaRen patients diagnosed with HFpEF are different from patients with HFrEF, with a rather high female representation, high mean weight and a high proportion of underlying hypertension. The mean LVEF at admission (56%) was comparable to patients in the OPTIMIZE-HF registry [21] , but KaRen patients more often had a history of atrial fibrillation [22] . Mean age was high (77 ± 9 years) and underlying diabetes, coronary artery disease and COPD were reported less often than in most previous studies [15] [16] [17] 22] . Patients included in KaRen are thus slightly different from patients previously described, mainly in the United States of America. Only 40% of KaRen patients had a prior heart failure admission, which is much lower than in registries such as ADHERE [23] (63%) and CHARM-Preserved [24] (69%) and may reflect the unselective nature of our study. This may in part also account for the low shortterm mortality. The patient profile in KaRen was driven by the fact that patients were admitted only in large hospitals and their dominant symptoms were linked to heart failure. They were admitted and examined in cardiology units. The mean blood pressure of 150/77 mmHg in KaRen is comparable to ADHERE [23] (152/79 mmHg). In KaRen and ADHERE, patients were included after an acute decompensation (main diagnosis). In OPTIMIZE-HF, blood pressure was lower (129/72 mmHg), but patients were recruited according to whether they had signs or symptoms of heart failure as a primary discharge diagnosis [14, 25, 26] . There are several characteristics and clinical presentations of HFpEF that are not necessarily different from HFrEF. In spite of different baseline characteristics, the acute clinical presentation in KaRen was similar to HFpEF and HFrEF patients [22, 26] . As in the OPTMIZE-HF registry [14] , 69% of patients presented with signs of left ventricular and right ventricular failure and only 24% presented with isolated left ventricular failure. Definitively, it is not possible to distinguish HFrEF and HFpEF patients based on clinical presentation alone [14, 15] .
It is known that about 50% of patients with HFrEF or HFpEF are discharged from hospital with residual signs of congestion [27] . We did not measure body weight at the time of discharge. However, weight was only reduced by a mean of 1 kg at the 4-8-week follow-up compared to hospital admission, suggesting insufficient treatment of congestion at the acute admission in spite of a mean hospital stay of 5 days and relatively high usage of diuretics. More evidence for insufficient therapy is the fact the NT-proBNP and BNP levels remained high even at 4-8 weeks. It is natural to assume that one of the reasons for this insufficient improvement is a lack of guideline-indicated treatments besides diuretics and drugs for hypertension [10] . However, this is not the only reason since HFrEF patients, despite guidelines for highly beneficial treatment, have the same proportion of insufficient improvements [27] . According to the treatments prescribed in patients included in KaRen, beta-blockers, diuretics, aldosterone antagonists and other blockers of the renin angiotensin system were prescribed in similar proportions to previous reports [28] .
Echocardiographic characteristics
Left ventricular ejection fraction > 45% does not mean that there is no anatomic or functional reason to develop signs and symptoms or heart failure [14, 29] . Most patients had left ventricular concentric remodelling or increase in left ventricular mass with an abnormal left ventricular longitudinal function (left ventricular: LV-s' 7.3 ± 2.0 cm/s or GLS -14.6 ± 3.9%). These patients had also diastolic dysfunction (depressed e' 7.9 ± 2.6 cm/s and large left atrium). Still, after 4-8 weeks of dedicated treatment, a large number of patients kept the association E/e > 12 and enlarged left atrium (Fig. 3) . However, these abnormalities of the systolic and diastolic functions of the left heart were not observed in every patient. In I-PRESERVE, the left atrium was normal in 34% of the population and diastolic function was classified as normal in 31% [29] . These left heart dysfunctions are frequently associated with right heart abnormalities that might also be more obvious than any left heart remodelling [30] . The right heart longitudinal function is frequently depressed (RV s 11 ± 3 cm/s; RV longitudinal strain-19 ± 5%, TAPSE 17 ± 6 mm) and the estimated pulmonary pressure after 4-8 weeks of treatment of the congestion remains high in many patients (tricuspid regurgitation 2.9 ± 0.6 m/s). The prevalence of electrical and mechanical dyssynchrony was low (LBBB 3.8%). Nevertheless, new sophisticated and, very probably, more appropriate tools to characterize mechanical dyssynchrony (like strain peaks dispersion) should very probably be looked for in this population [31] . Also, it would be relevant to measure the strain delay index, which has been elegantly demonstrated as clearly abnormal in 38 patients with HFpEF [32] . Further work is thus required before affirming that the majority of patients included in KaRen have no significant mechanical dyssynchrony that might affect myocardial function efficiency and prognosis.
Limitations
The present report is limited to the assessment of HFpEF patients during two phases of their disease: at admission for acute decompensation and 4-8 weeks later after treatment optimization. A complete and analysable echocardiographic recording was unfortunately only available for 356/539 patients (66%). Despite informed consent at baseline, these 76 did not return to the hospital for their scheduled 4-8week visit. They all explained that they felt too old and dependent to justify any further displacement to the hospital. It was evident that many HFpEF patients did not complain between acute episodes despite the presence of signs and symptoms. They were considering their health status as mainly linked to their age. A comparison of the characteristics of patients who had an echocardiography versus those who did not showed any difference. The baseline echocardiography had to be performed within the first 72 hours after admission, but did not have to be digitally recorded and complete; it was just to assess LVEF. Only the 4-8-week echocardiography had to be fully digitally recorded and re-interpreted at the core laboratory for echocardiography. The current guidelines define LVEF ≥ 50% as abnormal [10] . In KaRen, LVEF was 45-49% for 15% of the population, the others have as required by current guidelines, a LV EF ≥ 50%.
Conclusions
Patients in KaRen were old with slight female dominance, a high rate of hypertension and much co-morbidity. LVEF was preserved despite depressed left ventricular longitudinal and diastolic functions. Electric dyssynchrony does not seem to be a strong determinant in HFpEF. After 4-8 weeks of dedicated treatment, an important proportion of patients still showed symptoms and signs of heart failure.
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